Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

Global Antifungal Surveillance Group

Research output: Contribution to journalReview article

217 Citations (Scopus)

Abstract

Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test results were not analyzed. Overall, 90.1% of all Candida isolates tested were susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75% S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of Candida spp. tested against voriconazole, 94.8% were S and 3.1% were R. Less than 30% of fluconazole-resistant isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.

Original languageEnglish (US)
Pages (from-to)1735-1745
Number of pages11
JournalJournal of clinical microbiology
Volume45
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Fluconazole
Candida
Yeasts
Rhodotorula
Azoles
Antifungal Agents
Quality Control
Voriconazole
Research Personnel
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

@article{b498becb158e4444b8f1fb04618b27e0,
title = "Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing",
abstract = "Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test results were not analyzed. Overall, 90.1{\%} of all Candida isolates tested were susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75{\%} S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of Candida spp. tested against voriconazole, 94.8{\%} were S and 3.1{\%} were R. Less than 30{\%} of fluconazole-resistant isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.",
author = "{Global Antifungal Surveillance Group} and Pfaller, {M. A.} and Diekema, {D. J.} and Gibbs, {D. L.} and Newell, {V. A.} and Meis, {J. F.} and Gould, {I. M.} and W. Fu and Colombo, {A. L.} and E. Rodriguez-Noriega and Jorge Finquelievich and Nora Tiraboschi and David Ellis and Dominique Fameree and {Van Den Abeele}, {Anne Marie} and Senterre, {Jean Marc} and Colombo, {Arnaldo Lopez} and Robert Rennie and Stephen Sanche and Hu Bijie and Yingchun Xu and Wang Fu and Zhong, {Nan Shan} and Pilar Rivas and {De Bedout}, Catalina and Matilde Mendez and Ricardo Vega and Nada Mallatova and Stanislava Dobiasova and Julio Ayabaca and Jeannete Zurita and M. Mallie and E. Candolfi and W. Fegeler and G. Haase and Rodloff, {A. C.} and W. Bar and V. Czaika and George Petrikos and Pusk{\'a}s Erzs{\'e}bet and Elisabeth Nagy and Mestyan Gyula and Radka Nikolova and Uma Banerjee and Nathan Keller and Vivian Tullio and Schito, {Gian Carlo} and Domenico D'Antonio and Pietro Martino and Peng, {N. G.Kee} and Celia Alpuche",
year = "2007",
month = "6",
day = "1",
doi = "10.1128/JCM.00409-07",
language = "English (US)",
volume = "45",
pages = "1735--1745",
journal = "Journal of Clinical Microbiology",
issn = "0095-1137",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005

T2 - An 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

AU - Global Antifungal Surveillance Group

AU - Pfaller, M. A.

AU - Diekema, D. J.

AU - Gibbs, D. L.

AU - Newell, V. A.

AU - Meis, J. F.

AU - Gould, I. M.

AU - Fu, W.

AU - Colombo, A. L.

AU - Rodriguez-Noriega, E.

AU - Finquelievich, Jorge

AU - Tiraboschi, Nora

AU - Ellis, David

AU - Fameree, Dominique

AU - Van Den Abeele, Anne Marie

AU - Senterre, Jean Marc

AU - Colombo, Arnaldo Lopez

AU - Rennie, Robert

AU - Sanche, Stephen

AU - Bijie, Hu

AU - Xu, Yingchun

AU - Fu, Wang

AU - Zhong, Nan Shan

AU - Rivas, Pilar

AU - De Bedout, Catalina

AU - Mendez, Matilde

AU - Vega, Ricardo

AU - Mallatova, Nada

AU - Dobiasova, Stanislava

AU - Ayabaca, Julio

AU - Zurita, Jeannete

AU - Mallie, M.

AU - Candolfi, E.

AU - Fegeler, W.

AU - Haase, G.

AU - Rodloff, A. C.

AU - Bar, W.

AU - Czaika, V.

AU - Petrikos, George

AU - Erzsébet, Puskás

AU - Nagy, Elisabeth

AU - Gyula, Mestyan

AU - Nikolova, Radka

AU - Banerjee, Uma

AU - Keller, Nathan

AU - Tullio, Vivian

AU - Schito, Gian Carlo

AU - D'Antonio, Domenico

AU - Martino, Pietro

AU - Peng, N. G.Kee

AU - Alpuche, Celia

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test results were not analyzed. Overall, 90.1% of all Candida isolates tested were susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75% S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of Candida spp. tested against voriconazole, 94.8% were S and 3.1% were R. Less than 30% of fluconazole-resistant isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.

AB - Fluconazole in vitro susceptibility test results for 205,329 yeasts were collected from 134 study sites in 40 countries from June 1997 through December 2005. Data were collected for 147,776 yeast isolates tested with voriconazole from 2001 through 2005. All investigators tested clinical yeast isolates by the CLSI M44-A disk diffusion method. Test plates were automatically read and results recorded with a BIOMIC image analysis system. Species, drug, zone diameter, susceptibility category, and quality control results were collected quarterly. Duplicate (same patient, same species, and same susceptible-resistant biotype profile during any 7-day period) and uncontrolled test results were not analyzed. Overall, 90.1% of all Candida isolates tested were susceptible (S) to fluconazole; however, 10 of the 22 species identified exhibited decreased susceptibility (<75% S) on the order of that seen with the resistant (R) species C. glabrata and C. krusei. Among 137,487 isolates of Candida spp. tested against voriconazole, 94.8% were S and 3.1% were R. Less than 30% of fluconazole-resistant isolates of C. albicans, C. glabrata, C. tropicalis, and C. rugosa remained S to voriconazole. The non-Candida yeasts (8,821 isolates) were generally less susceptible to fluconazole than Candida spp. but, aside from Rhodotorula spp., remained susceptible to voriconazole. This survey demonstrates the broad spectrum of these azoles against the most common opportunistic yeast pathogens but identifies several less common yeast species with decreased susceptibility to antifungal agents. These organisms may pose a future threat to optimal antifungal therapy and emphasize the importance of prompt and accurate species identification.

UR - http://www.scopus.com/inward/record.url?scp=34250621370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250621370&partnerID=8YFLogxK

U2 - 10.1128/JCM.00409-07

DO - 10.1128/JCM.00409-07

M3 - Review article

C2 - 17442797

AN - SCOPUS:34250621370

VL - 45

SP - 1735

EP - 1745

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

SN - 0095-1137

IS - 6

ER -